(2) LSM >11 KPa could be used to identify patients who may have lower response rates and may benefit from longer treatment.

P19 SYMPTOMATIC EPSTEIN BARR VIRUS (EBV) HEPATITIS IS UNCOMMON, BUT OCCURS IN PATIENTS OF ANY AGE, INCLUDING THE ELDERLY

doi:10.1136/gutjnl-2011-300857a.19

L Vine, K Sheppard, D Grimes, R Bendall, H Dalton. Royal Cornwall Hospital Trust

Introduction Epstein Barr Virus (EBV) infection typically presents as infectious mononucleosis (IM) in young adults with the classical triad of fever, sore throat and lymphadenopathy. Mildly abnormal liver function tests (LFTs) are common but symptomatic hepatitis is rare. Symptomatic, icteric, EBV hepatitis is rarely reported in those with IM and in the elderly.

Aim To review the demographics, presenting features and natural history with EBV hepatitis and to determine what factors might lead a clinician to consider a diagnosis of EBV hepatitis.

Method Retrospective study of 2100 patients attending the Jaundice Hotline, a fast track referral system for patients with jaundice at The Corwell Royal Cornwall Hospital (1998–2011). EBV hepatitis was defined as: symptomatic hepatitis with positive serology for EBV (serology included EBV nuclear antigen, EBV viral capsid antigen (VCA) IgM and VCA IgG). All patients had no evidence of biliary obstruction or parenchymal liver disease on abdominal ultrasound examination (USS), and negative serology for other hepatotropic viruses (HAV, HBV, HCV, HEV, CMV). Other causes of parenchymal liver disease were also excluded by appropriate blood tests.

Results Of the total of 2100 consecutive patients with jaundice studied, 17 patients (10 males, 7 females) were diagnosed with EBV hepatitis. All patients were immunocompetent. 47% (8/17) of these patients were aged over 44 years (mean age 44 years, range 18–82). At presentation, mean (range) LFTs were: bilirubin 57 μmol/l (11–161), ALT 428 IU/l (64–1471), ALKF 339 IU/l (132–840). Only 3 patients presented as classical IM. 95% (16/17) had significant lymphocytosis and 82% (14/17) patients had splenomegaly on USS examination at initial assessment. Only 2 patients were unwell enough to be admitted to hospital. All patients fully recovered within 4–6 weeks.

Conclusion Symptomatic EBV hepatitis is uncommon and causes a self-limiting illness. EBV hepatitis is not usually associated with classical symptoms of IM and occurred in patients of a wide variety of ages. The diagnosis should be considered in patients of all ages presenting with hepatitis, including those with a cholestatic picture, and especially in those with a lymphocytosis and splenomegaly.

P20 FIRST REPORT OF THE LONG-TERM EFFICACY OF A NOVEL ENDOSCOPIC RADIOFREQUENCY ABLATION TECHNIQUE FOR MALIGNANT BILIARY OBSTRUCTION

doi:10.1136/gutjnl-2011-300857a.20

1Y Kallis, 2N Phillips, 2A Steel, 3C Baldwin, 4J Nicholls, 4L Jiao, 1P Vlavianos, 4N Habib, 1D Westaby. 1Department of Gastroenterology, Imperial College Healthcare, London; 2Department of Gastroenterology, Chelsea and Westminster Hospital London; 3Faculty of Medicine, Imperial College, London; 4Academic Department of Surgery, Hamme-smith Hospital, Imperial College, London

Introduction Insertion of self-expanding metal stents (SEMS) is standard practice in patients with unresectable malignant biliary strictures. Stent occlusion is a significant clinical problem in patients surviving beyond 3 months. A pioneering phase I/II study in our tertiary referral centre demonstrated good safety and 30-day patency using a novel endoscopic radiofrequency ablation (RFA) technique as an adjunct to SEMS.1 The longer term impact of combined RFA +SEMS on biliary drainage and overall patient survival is unknown.

Aim To investigate long-term safety and efficacy of endobiliary RFA in malignant bile duct obstruction.

Method Retrospective cohort analysis of 24 patients undergoing RFA +SEMS (17 pancreatic carcinoma; 7 cholangiocarcinoma) and 44 matched controls undergoing SEMS insertion alone (34 pancreatic carcinoma, 10 cholangiocarcinoma) for malignant biliary obstruction in a single tertiary referral centre. Patients were matched for age, sex, disease, presence of metastases, ASA/co-morbidities, and intention to treat with palliative chemotherapy. Patients with a potential minimum of 6-month follow-up were included and survival, maintenance of stent patency and procedure-related complications were assessed.

Results RFA treated and control cohorts were closely matched-mean age 71.8±9.8 yrs vs 68.8±10.3, metastases at treatment 9/24 (38%) vs 17/44 (39%), chemotherapy 16/24 (67%) vs 27/44 (61%). Kaplan–Meier analysis showed a median survival of 227 days in the RFA group vs 159 days in controls (p=0.067). Multivariate analysis showed RFA treatment to be the strongest predictor of survival at 90 days (OR 2.8, p=0.011). Survival benefits may extend beyond 90 days (OR 2.8, p=0.071 at 180 days; OR 2.8, p=0.102 at 360 days), but require further investigation. Within 6 months after treatment, more patients were alive with a patent RFA group than in controls. Complications of RFA were few (1 pancreatitis, 2 cholecystitis) and comparable to those associated with standard ERCP alone. The procedure was well-tolerated with a median post-procedure inpatient stay of 1 day (1–24).

Conclusion In the single largest case series studied to date, endobiliary RFA is a safe and efficacious treatment for malignant biliary obstruction, with potential early survival benefit. Large multi-centre prospective trials of this novel treatment modality are warranted.

REFERENCE


P21 ACTIVELY INJECTING DRUG USERS CAN BE SUCCESSFULLY TREATED WITH ANTIVIRAL THERAPY FOR HCV, ARE UNLIKELY TO BE RE-INFECTED, AND SIGNIFICANTLY REDUCE THEIR ILLICIT DRUG USE

doi:10.1136/gutjnl-2011-300857a.21

1H Lewis, 2N Ibrahim, 3M Mirza, 2J Hoti, 2M Wilkinson, 1G Foster. 1Queen Mary University of London, 2Barts and the London School of Medicine and Dentistry, 3East London NHS Foundation Trust

Introduction Currently the predominant mode of transmission of hepatitis C virus (HCV) in the developed world is injection drug use
(IDU) and HCV antibody prevalence rates reach 60–90% in those who have injected drugs. Treatment rates of injecting drug users (IDU’s) with HCV are low at just 3–10% and although small studies indicate treatment of IDU’s is safe and effective, data on outcomes of antiviral therapy in current injecting drug users is limited with the largest study published to date including just 31 active IDU’s. It has been suggested that antiviral therapy for HCV use may reduce illicit drug use, but published data to support this is lacking.

**Aim**

To assess the treatment outcomes and the impact of antiviral therapy on illicit drug use in injecting drug users (IDU’s) treated with antiviral therapy for Hepatitis C virus (HCV) by nurses based in community addiction services in North East London. The outcomes of the first 81 patients to be treated are presented here, 48 of whom were using illicit drugs at the start of treatment making this the largest cohort of active IDU’s with HCV treated with antiviral therapy that has been presented to date.

**Method**

Methods consisted of a retrospective database analysis. Illicit drug use was quantified as 3 (heavy/daily); 2 (weekly/moderate); 1 (monthly/occasional) and 0 (previous drug use). The Wilcoxon signed rank test was used for statistical analysis.

**Results**

81 patients were treated over a 48-month period from September 2004 to January 2009. 50 (62%) were genotype 2/3, and 31 (38%) were genotype 1. The average age of infection with HCV was 23, of diagnosis was 39 and of treatment was 41. Compliance with treatment was 88%. 63% of patients had a sustained viral response, 18% were non-responders and 10% discontinued treatment early due to side effects. 5 patients (6%) relapsed after successful treatment. Only 1 patient (1%) has been re-infected post treatment. 48 patients (60%) were actively using illicit drugs when HCV treatment was initiated. Data on pre and post treatment intravenous heroin use, crack cocaine use and alcohol use was available in 74, 40 and 21 patients respectively. Intravenous heroin use reduced from 41/74 patients (55%) to 27/74 (36%) (p=0.0033) after treatment, with daily use reducing from 16/74 (22%) to 7/74 (9%). Crack cocaine use reduced from 32/40 (80%) to 21/40 (53%) (p=0.0103) Alcohol use reduced from 15/21 (71%) to 13/21 (62%) (p=0.5775).

**Conclusion**

Nurse led provision of antiviral therapy for HCV infected injecting drug users in community based clinics is effective, with sustained viral response (SVR) rates that compare favourably with published randomised controlled trials of pegylated interferon and ribavirin. High rates of compliance are seen and re-infection rates are low, so concern over compliance and re-infection should not prevent treatment of injecting drug users. This study has shown for the first time that a significant reduction in illicit drug use occurs during and after antiviral therapy demonstrating a social benefit of treatment in addition to the known health benefits.

**REFERENCE**